Fabtech Technologies Cleanrooms Ltd
Incorporated in 2015, Fabtech Technologies Cleanrooms Limited is a global company specializing in turnkey engineering solutions for the pharmaceutical, biotech, and healthcare sectors.[1]
- Market Cap ₹ 387 Cr.
- Current Price ₹ 314
- High / Low ₹ 470 / 203
- Stock P/E 24.4
- Book Value ₹ 84.1
- Dividend Yield 0.64 %
- ROCE 19.7 %
- ROE 16.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 84.5% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Industrial Manufacturing Industrial Products
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 89 | 70 | 114 | 125 | 97 | 150 | 219 | |
| 83 | 69 | 107 | 112 | 89 | 134 | 198 | |
| Operating Profit | 6 | 1 | 6 | 13 | 8 | 16 | 21 |
| OPM % | 7% | 2% | 5% | 10% | 9% | 11% | 10% |
| 1 | 0 | 0 | 0 | 1 | 1 | 2 | |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 0 | 1 | 2 |
| Profit before tax | 6 | 1 | 5 | 12 | 7 | 16 | 21 |
| Tax % | 28% | -42% | 29% | 31% | 27% | 24% | 20% |
| 4 | 1 | 4 | 8 | 6 | 13 | 17 | |
| EPS in Rs | 1,333.33 | 250.00 | 12.92 | 28.57 | 19.99 | 10.80 | 12.84 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 19% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 21% |
| TTM: | 46% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 84% |
| 3 Years: | 26% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 16% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 3 | 3 | 3 | 12 | 12 |
| Reserves | 31 | 32 | 35 | 43 | 49 | 82 | 91 |
| 10 | 7 | 8 | 6 | 6 | 1 | 19 | |
| 26 | 30 | 36 | 29 | 32 | 28 | 63 | |
| Total Liabilities | 67 | 69 | 82 | 81 | 89 | 124 | 186 |
| 4 | 5 | 4 | 4 | 5 | 4 | 8 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 1 | 27 | 10 |
| 63 | 64 | 77 | 76 | 83 | 93 | 168 | |
| Total Assets | 67 | 69 | 82 | 81 | 89 | 124 | 186 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -9 | 4 | 3 | 8 | 3 | 3 | -17 | |
| 2 | -1 | -4 | -3 | -2 | -26 | 1 | |
| 7 | -3 | 1 | -4 | -1 | 24 | 14 | |
| Net Cash Flow | 1 | -0 | -0 | 1 | 0 | 1 | -2 |
| Free Cash Flow | -12 | 3 | 2 | 8 | 1 | 0 | -27 |
| CFO/OP | -115% | 292% | 52% | 80% | 71% | 41% | -72% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 181 | 221 | 165 | 144 | 193 | 129 | 146 |
| Inventory Days | 63 | 95 | 63 | 57 | 88 | 67 | 81 |
| Days Payable | 114 | 146 | 105 | 82 | 122 | 74 | 85 |
| Cash Conversion Cycle | 130 | 170 | 123 | 119 | 160 | 122 | 142 |
| Working Capital Days | 112 | 144 | 92 | 95 | 139 | 124 | 111 |
| ROCE % | 2% | 14% | 26% | 16% | 21% | 20% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Installed Manufacturing Space sq. ft. ・Standalone data |
|
||
| Consolidated Order Book ₹ Crores |
|||
| Total Employee Count Number ・Standalone data |
|||
| Number of Clients Nodes ・Standalone data |
|||
| Order Pipeline (Leads) ₹ Crores |
|||
| Panel Manufacturing Capacity Utilization % ・Standalone data |
|||
| Revenue Mix - Non-Pharma % |
|||
| Revenue Mix - Pharma % |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Posted video recording link for May 5, 2026 earnings call on audited FY26 results.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Apr - Regarding Newspaper Publication for Audited Financial Result of the company for Second half Year ended and Year ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
29 Apr - Investor Presentation for the Audited Standalone and Consolidated Financial Results of the company for the half year ended and year ended March 31st, 2026.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
29 Apr - Fabtech reported FY26 audited results: revenue ₹221.72 Cr, PAT ₹15.82 Cr, order book above ₹199 Cr.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
29 Apr - Earnings conference call on May 5, 2026 at 12:00 PM for H2 FY26 and FY26 audited results.
Annual reports
Concalls
-
Apr 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT
-
Jun 2025TranscriptPPT
-
Mar 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
Business Overview[1]
Fabtech Technologies Cleanrooms specializes in manufacturing and providing end-to-end solutions for pre-engineered and pre-fabricated modular panels and doors for cleanrooms. These cleanrooms are used in pharmaceutical, healthcare, and biotech sectors and adhere to global regulatory standards like ISO and FDA. The company offers services including design, engineering, manufacturing, quality assurance, installation, and validation.